RxDoctor Payments Data

Stephen Gist, MD

Internal Medicine · Dallas, TXNPI 1770555450

Payments from drug & device makers

$2,501in general payments, 2019–2025

Across 147 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$594
  • AbbVie$294
  • Novo Nordisk$280
  • GSK$147
  • Amgen$147
  • Boehringer Ingelheim$142
  • plus $896 from 24 others

What the payments were for

  • Food & beverage$2,501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,501 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$165,987
Medicare patients
138
Services billed
4,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$56,573
EliquisApixaban49$44,938
XareltoRivaroxaban29$26,499
JardianceEmpagliflozin30$24,030
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$14,451
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,087
FarxigaDapagliflozin Propanediol12$7,035
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,696
Levothyroxine Sodium203$2,550
SynthroidLevothyroxine Sodium27$2,028
Atorvastatin Calcium159$2,004
Celecoxib34$1,664
Tamsulosin Hcl80$1,647
Amlodipine Besylate193$1,165
Lisinopril147$1,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$280$56,57351 claims
PfizerEliquis$594$44,93849 claims
Johnson & JohnsonXarelto$14$26,49929 claims
Boehringer IngelheimJardiance$142$24,03030 claims
GSKTrelegy Ellipta$147$14,08714 claims
AstraZenecaFarxiga$115$7,03512 claims
AbbVieSynthroid$294$2,02827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →